Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Selecta Biosciences Inc.
DescriptionNon‑immunogenic therapy comprising SVP-Rapamycin co-administered with pegsiticase, a pegylated uricase
Molecular Target Uric acid
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase I
Standard IndicationHyperuricemia / gout
Indication DetailsTreat refractory and tophaceous gout
Regulatory Designation
Partner3SBio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today